Unassociated Document

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported)
January 4, 2010
 
VARIAN MEDICAL SYSTEMS, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
1-7598
94-2359345
(State or Other Jurisdiction
of Incorporation)
(Commission File
Number)
(IRS Employer
 Identification No.)
 
3100 Hansen Way, Palo Alto, CA
94304-1030
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant's telephone number, including area code
(650) 493-4000
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item 8.01.
Other Events
 
On January 4, 2010, Varian Medical Systems, Inc. (“Varian”) was informed that Skandion Kliniken (“Skandion”) intends to cancel the award to Varian of a $62 million order for a proton therapy system.  Skandion awarded Varian the contract for the proton therapy system following a public tender process that was subsequently challenged by a competitor.  As Varian announced in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 4, 2009, the Swedish court ruled on December 3, 2009, that the tender should be recommenced.
 
As a result of the cancellation, Varian intends to remove the order from its backlog in the first fiscal quarter of 2010.  Varian does not believe that this will have an effect on its previously announced revenue and earnings guidance for fiscal year 2010.
 
1
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Varian Medical Systems, Inc.
     
     
 
By:
 /s/ JOHN W. KUO
 
Name:
John W. Kuo
 
Title:
Corporate Vice President, General Counsel and Secretary
 
Dated:  January 6, 2010
 
2